A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

The U.S. National Transportation Safety Board on Monday said more than 40 foreign operators of Boeing 737 airplanes may be ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

From financing the future of cleaner energy to influencing trades at the world's largest hedge fund, here's why these ...

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

Dr Joseph Berger reviews findings showing how newer drugs like satralizumab, eculizumab, and inebilizumab outperformed older neuromyelitis optica spectrum disorder treatments.

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...